Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat
GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.
|Fireside Chat details:
||Tuesday, March 9, 2021
||Available on-demand starting at 7:00 a.m. Eastern Time (ET)
||Gregory M. Glenn, M.D., President, Research and Development and John Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Erika Schultz | 240-268-2022
Jennifer Porcelli | 617-974-8659
Amy Speak | 617-420-2461
Laura Keenan | 410-419-5755